Last reviewed · How we verify
Pharmorubicin
At a glance
| Generic name | Pharmorubicin |
|---|---|
| Also known as | epirubicin |
| Sponsor | Zhejiang Cancer Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma (PHASE2)
- Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma (PHASE2, PHASE3)
- Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors (PHASE2)
- Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. (PHASE1, PHASE2)
- Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients (PHASE3)
- Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients (PHASE2)
- Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells (PHASE2)
- Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pharmorubicin CI brief — competitive landscape report
- Pharmorubicin updates RSS · CI watch RSS
- Zhejiang Cancer Hospital portfolio CI